Back

Prevalence of transthyretin amyloid cardiomyopathy in patients hospitalised for heart failure with preserved ejection fraction in an LATAM center.

31 August 2024 (10:00 - 10:50)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis, sarcoidosis, and inflammation Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Santiago Decotto

Italian Hospital of Buenos Aires, Buenos Aires (Argentina)

8 More presentations in this session

Presentation thumbnail
Delays in diagnosis and treatment initiation of ATTR cardiac amyloidosis: a real-world data analysis
Doctor J. Vogel (Essen, DE)
Abstract Slides Video
Presentation thumbnail
Transthyretin stabiliser therapy in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis
Mr V. Ribeiro (Teresina, BR)
Abstract Slides Video
Presentation thumbnail
Biomarkers for monitoring patients with cardiac amyloidosis during transthyretin-stabilizer therapy
Doctor J. Vogel (Essen, DE)
Abstract Slides
Presentation thumbnail
Relationship between changes in renal function after acute phase of tafamidis administration and left ventricular diastolic function at mid-term follow-up in transthyretin cardiac amyloidosis
Ms A. Senda (Kobe, JP)
Abstract Slides
Presentation thumbnail
Prevalence of amyloidosis among patients with mild to severe aortic stenosis. Validation of screening parameters.
Doctor F. Voss (Duesseldorf, DE)
Abstract Slides

Access the full session

Session thumbnail
Cardiac amyloidosis, sarcoidosis, and inflammation

The Event

Event poster

ESC Congress 2024

31 August 2024 10:00 CET
You may be interested in
thumbnail
Congress Presentation
International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction
thumbnail
Congress Presentation
True prevalence of transthyretin cardiac amyloidosis in an unselected heart failure with preserved ejection fraction cohort
thumbnail
Congress Presentation
Impact of the implementation of a checklist for the screening and diagnosis of cardiac amyloidosis in patients with heart failure (CHECKAMIC)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources